A detailed history of Nisa Investment Advisors, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 1,587 shares of ARVN stock, worth $38,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,587
Previous 1,535 3.39%
Holding current value
$38,849
Previous $63,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$24.46 - $40.4 $1,271 - $2,100
52 Added 3.39%
1,587 $42,000
Q1 2024

May 01, 2024

BUY
$36.38 - $52.31 $1,273 - $1,830
35 Added 2.33%
1,535 $63,000
Q4 2023

Jan 25, 2024

BUY
$14.19 - $42.33 $3,547 - $10,582
250 Added 20.0%
1,500 $61,000
Q3 2023

Nov 02, 2023

BUY
$19.64 - $28.21 $13,158 - $18,900
670 Added 115.52%
1,250 $24,000
Q2 2023

Aug 11, 2023

SELL
$21.73 - $31.43 $15,819 - $22,881
-728 Reduced 55.66%
580 $14,000
Q1 2023

May 02, 2023

SELL
$26.15 - $37.26 $1,621 - $2,310
-62 Reduced 4.53%
1,308 $36,000
Q4 2022

Feb 02, 2023

SELL
$32.47 - $57.24 $454 - $801
-14 Reduced 1.01%
1,370 $47,000
Q3 2022

Nov 07, 2022

BUY
$41.87 - $57.99 $11,891 - $16,469
284 Added 25.82%
1,384 $69,000
Q2 2022

Aug 03, 2022

SELL
$36.01 - $74.24 $1,440 - $2,969
-40 Reduced 3.51%
1,100 $46,000
Q1 2022

Apr 29, 2022

SELL
$60.27 - $81.57 $94,864 - $128,391
-1,574 Reduced 58.0%
1,140 $77,000
Q4 2021

Feb 03, 2022

BUY
$65.85 - $96.21 $66,771 - $97,556
1,014 Added 59.65%
2,714 $194,000
Q2 2021

Aug 06, 2021

SELL
$60.45 - $84.26 $800,962 - $1.12 Million
-13,250 Reduced 88.63%
1,700 $131,000
Q1 2021

Apr 26, 2021

BUY
$58.19 - $91.37 $842,009 - $1.32 Million
14,470 Added 3014.58%
14,950 $988,000
Q4 2020

Jan 25, 2021

BUY
$20.19 - $84.93 $1,009 - $4,246
50 Added 11.63%
480 $41,000
Q2 2020

Jul 27, 2020

BUY
$29.88 - $56.74 $12,848 - $24,398
430 New
430 $14,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.3B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.